US EditionPublished • loading... • Updated
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
- Hyundai Bioscience presented preclinical results of Penetrium combinations at AACR 2025 in Chicago on May 7, 2025, showing a breakthrough in cancer treatment.
- The research identified extracellular matrix stiffening, causing pseudo-resistance, as the main cause of immunotherapy failure in cold tumors rather than genetic resistance.
- Penetrium remodels the stiffened extracellular matrix to restore infiltration and enable immune cells and drugs to reach tumors, reducing tumor burden and metastasis in various models.
- In a spontaneous canine breast cancer study, the combination of Penetrium and POLYTAXEL reduced the size of primary tumors by 38.7% and decreased metastatic lymph node tumor volume by nearly 79%, indicating a stronger response in metastatic sites and challenging the belief that metastatic cancer cannot be effectively treated.
- These findings confirm Penetrium's readiness for human trials and its potential as a tumor-agnostic cancer therapy platform targeting multiple cancers including TNBC and AML.
Insights by Ground AI
40 Articles
40 Articles
Farm Talk Newspaper+38 Reposted by 38 other sources
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
Penetrium™ Achieves Historic BreakthroughOvercoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody TherapyPresented at AACR 2025, Chicago
·Parsons, United States
Read Full Article
London – Clonal hematopoiesis of undetermined potential (CHIP), previously considered only a possible precursor to acute myeloid leukemia, may also influence the risk of other cancers. A study in the New England Journal of Medicine (2025; DOI: 10.1056/NEJMoa2413361) suggests that tumor-infiltrating clonal...
Coverage Details
Total News Sources40
Leaning Left2Leaning Right2Center12Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
13%
C 75%
12%
Factuality
To view factuality data please Upgrade to Premium
